Immunobiology Limited
Research and experimental development on biotechnology · Newbury
ActiveUnited KingdomIncorporated 1999Private Limited Company
Documents & history
Available account evidence and business events. This is not a complete filing history or document library.
Accounts to 2025-05-31
IXBRL · 94 source facts · 19 selected values
Validation findingsXBRL valid
Accounts to 2025-05-31
IXBRL · 94 source facts · 19 selected values
Validation findings
XBRL valid
- Reporting period
- 2024-06-01 to 2025-05-31
- Extraction status
- complete
- Numeric facts
- 59
- Documents processed
- 1
- XBRL standards validation
- valid
- Filing-profile validation
- invalid
- Parser
- arelle 2.44.4
- Taxonomy
- FRS-102-2025-01-01.xsd
- Currency
- GBP
- Source identifier
- Prod224_2607_03777578_20250531
- Source archive
- Accounts_Monthly_Data-July2026.zip
Extraction findings: filing rules invalid. These describe source processing, not an audit opinion on the company.
Accounts to 2024-05-31
IXBRL · 45 source facts · 18 selected values
Validation findingsXBRL valid
Accounts to 2024-05-31
IXBRL · 45 source facts · 18 selected values
Validation findings
XBRL valid
- Reporting period
- 2023-06-01 to 2024-05-31
- Extraction status
- complete
- Numeric facts
- 26
- Documents processed
- 1
- XBRL standards validation
- valid
- Filing-profile validation
- invalid
- Parser
- arelle 2.44.4
- Taxonomy
- FRS-102-2023-01-01.xsd
- Currency
- GBP
- Source identifier
- Prod224_2505_03777578_20240531
- Source archive
- Accounts_Monthly_Data-May2025.zip
Extraction findings: filing rules invalid. These describe source processing, not an audit opinion on the company.
Accounts to 2023-05-31
IXBRL · 67 source facts · 23 selected values
Not assessedlegacy record
Accounts to 2023-05-31
IXBRL · 67 source facts · 23 selected values
Not assessed
legacy record
- Reporting period
- 2022-06-01 to 2023-05-31
- Extraction status
- Legacy / not assessed
- Numeric facts
- 36
- Documents processed
- Not recorded
- XBRL standards validation
- Not assessed
- Filing-profile validation
- Not assessed
- Parser
- Legacy parser
- Taxonomy
- FRS-102-2023-01-01.xsd
- Currency
- GBP
- Source identifier
- Prod224_2166_03777578_20230531
- Source archive
- Accounts_Monthly_Data-May2024.zip
Accounts to 2021-05-31
IXBRL · 106 source facts · 20 selected values
Not assessedlegacy record
Accounts to 2021-05-31
IXBRL · 106 source facts · 20 selected values
Not assessed
legacy record
- Reporting period
- 2020-06-01 to 2021-05-31
- Extraction status
- Legacy / not assessed
- Numeric facts
- 48
- Documents processed
- Not recorded
- XBRL standards validation
- Not assessed
- Filing-profile validation
- Not assessed
- Parser
- Legacy parser
- Taxonomy
- FRS-102-2019-01-01.xsd
- Currency
- GBP
- Source identifier
- Prod224_0098_03777578_20210531
- Source archive
- Accounts_Monthly_Data-December2021.zip
Accounts to 2020-05-31
IXBRL · 276 source facts · 30 selected values
Not assessedlegacy record
Accounts to 2020-05-31
IXBRL · 276 source facts · 30 selected values
Not assessed
legacy record
- Reporting period
- 2019-06-01 to 2020-05-31
- Extraction status
- Legacy / not assessed
- Numeric facts
- 186
- Documents processed
- Not recorded
- XBRL standards validation
- Not assessed
- Filing-profile validation
- Not assessed
- Parser
- Legacy parser
- Taxonomy
- FRS-102-2019-01-01.xsd
- Currency
- GBP
- Source identifier
- Prod224_0080_03777578_20200531
- Source archive
- Accounts_Monthly_Data-July2020.zip
Registered details
03777578- Status
- Active
- Type
- Private Limited Company
- Incorporated
- 1999-05-26
- Jurisdiction
- —
- Registered office
- 2 COMMUNICATIONS ROAD, GREENHAM BUSINESS PARK, NEWBURY, BERKSHIRE, RG19 6AB, UNITED KINGDOM
Classification
1 SIC codes72110
Capital & company events
Reconstructed equity rounds and matched research funding.
Equity fundraising
1 SH01-derived rounds2025-05-13
£210,000 raised
£3,482,569 estimated post-money
Research and innovation
5 matched grantsLow cost, broadly efficacious Pneumococcal vaccineLead
Innovate UK · Feasibility Studies · 2013-04-01 – 2014-03-31
£146,993
awarded
Market viability of ImmBioVax vaccines against H. Pylori and C. DifficileLead
Innovate UK · GRD Proof of Market · 2013-03-01 – 2013-09-30
£24,500
awarded
Development of a Universal Meningococcal VaccineLead
Innovate UK · Collaborative R&D · 2012-12-01 – 2014-05-31
£490,000
awarded
Manufacture of Low Cost High Efficacy VaccineLeadInnovate UK · Collaborative R&D · 2009-10-01 – 2011-09-30 · with 2 other participants£178,881awarded
Manufacture of Low Cost High Efficacy VaccineLead
Innovate UK · Collaborative R&D · 2009-10-01 – 2011-09-30 · with 2 other participants
£178,881
awarded
Biomanufacture of HspC Vaccines Against Bacterial PathogensLeadInnovate UK · Collaborative R&D · 2007-09-01 – 2009-08-31 · with 2 other participants£12,929awarded
Biomanufacture of HspC Vaccines Against Bacterial PathogensLead
Innovate UK · Collaborative R&D · 2007-09-01 – 2009-08-31 · with 2 other participants
£12,929
awarded